News & Updates

Show Multimedia Only

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

03 Oct 2025 by

Compared with tirzepatide, subcutaneous semaglutide 2.4 mg is associated with a 57 percent lower risk of revised 3-point major adverse cardiovascular events (3P-MACE; defined as MI, stroke, and all-cause mortality [instead of cardiovascular-related death]) in a population similar to the SELECT trial — patients with overweight or obesity and established atherosclerotic cardiovascular disease (ASCVD) but no history of diabetes, according to results of the real-world STEER trial presented at the European Society of Cardiology (ESC) Congress 2025.

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

03 Oct 2025

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

26 Sep 2025 by

A 57-year-old male lorry driver, who was an ex-chronic smoker and had underlying chronic diseases, was hospitalized due to a 3-day history of fever, cough, and shortness of breath in April 2025.

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

26 Sep 2025

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

16 Sep 2025

Stepping up to triple therapy with inhaled corticosteroid (ICS) plus a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) inadequately controlled with dual therapy. The use of single-inhaler therapy has also been recommended over the use of multiple inhalers, as convenience has been associated with better treatment adherence and effectiveness. This article highlights the results of the first real-world comparative effectiveness study of two single-inhaler triple therapy (SITT) formulations, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and budesonide/ glycopyrrolate/formoterol fumarate (BUD/GLY/FORM), in patients who stepped up from prior dual combination therapy.

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

16 Sep 2025

Marked improvement of LVEF with an SGLT2i in a patient with nonischaemic HFrEF

10 Sep 2025 by

A 45-year-old female with a sedentary lifestyle presented with lower extremity oedema in 2023. She was slightly overweight (26 kg/m²) and had no prior history of cardiac disease. Her busy lifestyle precluded regular health check-ups.

Marked improvement of LVEF with an SGLT2i in a patient with nonischaemic HFrEF

10 Sep 2025

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

20 Aug 2025 by

The American Heart Association defines cardiovascular-kidney-metabolic (CKM) syndrome as the overlap between metabolic, kidney, and cardiovascular diseases (CVDs). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, offer benefits that extend beyond glycaemic control and weight loss to cardiorenal protection. In a symposium, Dr Julie Lovshin of the University of Toronto, Canada, shared clinical trial data on once-weekly subcutaneous (SC) semaglutide’s cardiorenal protective effects in different CKM patient populations. She also explored characteristics of optimal candidates for GLP-1 RA treatment.

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

20 Aug 2025

First experience with sotatercept for pulmonary arterial hypertension in Southern China

20 Aug 2025 by

A 77-year-old male chronic smoker with a history of diabetes mellitus, hypertension, coronary artery disease treated with stenting to left circumflex artery and ramus intermediate artery in 2015, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD) presented on 19 January 2024 with shortness of breath (SOB) on exertion, which began following an episode of COVID-19 in May 2023 and worsened after a subsequent COVID-19 episode in April 2024. Before the two COVID-19 episodes, the patient had good exercise tolerance and could manage a 1-hour hike.

First experience with sotatercept for pulmonary arterial hypertension in Southern China

20 Aug 2025

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025 by

Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic, progressive disorder associated with adverse outcomes in advanced stages. At an industry-sponsored symposium organized by the Hong Kong College of Family Physicians, experts discussed recommendations in the American Heart Association’s (AHA) presidential advisory on CKM health, strategies for early CKM intervention in primary care, as well as guideline recommendations and clinical trial results supporting the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i; eg, empagliflozin) in CKM syndrome.

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025

Advancing collaboration in COVID-19 care

16 Aug 2025

Held in June 2025 in Singapore, the Pfizer COVID-CONNECT Masterclass convened international experts to discuss the evolving challenges of COVID-19. Co-chaired by Dr Asok Kurup and Dr Luke Moore, this event assessed the ongoing global impact of the disease and explored evidence-based strategies across the patient journey from early identification to effective treatment.

Advancing collaboration in COVID-19 care

16 Aug 2025

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

At the recent COVID-CONNECT Masterclass, an expert-led session explored where COVID-19 stands among common viral infections today. In a non-promotional symposium supported by Pfizer, infectious disease specialist Dr Leong Hoe Nam, Mount Elizabeth Hospital Novena, Singapore, discussed strategies for managing viral infections and surge preparedness. Complementing this, Professor David Strain from the University of Exeter Medical School, UK highlighted the enduring burden of long COVID.

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

Closing LDL-C treatment gaps with nonstatin options: Insights from European registries

29 Jul 2025 by

Cardiovascular disease (CVD) accounts for nearly half of all deaths in Europe. Despite the introduction of lower LDL-cholesterol (LDL-C) treatment targets, effective LDL-C control remains challenging. At the Advances in Medicine (AIM) 2025 meeting, Professor Andreas Schäfer from Hannover Medical School, Hannover, Germany, discussed unmet needs in LDL-C control across Europe and shared new clinical insights on bempedoic acid.

Closing LDL-C treatment gaps with nonstatin options: Insights from European registries

29 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

ESC 2025: Semaglutide cuts MACE risk by 57 percent vs tirzepatide in patients with obesity and ASCVD

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

Marked improvement of LVEF with an SGLT2i in a patient with nonischaemic HFrEF

Marked improvement of LVEF with an SGLT2i in a patient with nonischaemic HFrEF

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

First experience with sotatercept for pulmonary arterial hypertension in Southern China

First experience with sotatercept for pulmonary arterial hypertension in Southern China

CKM syndrome: Strategies for early intervention in primary care

CKM syndrome: Strategies for early intervention in primary care

Advancing collaboration in COVID-19 care

Advancing collaboration in COVID-19 care

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

Closing LDL-C treatment gaps with nonstatin options: Insights from European registries

Closing LDL-C treatment gaps with nonstatin options: Insights from European registries